BR0212089A - Composições farmacêuticas para o tratamento de asma - Google Patents

Composições farmacêuticas para o tratamento de asma

Info

Publication number
BR0212089A
BR0212089A BR0212089-5A BR0212089A BR0212089A BR 0212089 A BR0212089 A BR 0212089A BR 0212089 A BR0212089 A BR 0212089A BR 0212089 A BR0212089 A BR 0212089A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
asthma treatment
asthma
treatment
formulations
Prior art date
Application number
BR0212089-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Joel A Siqueira
Stefan A Sharpe
John L Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0212089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0212089A publication Critical patent/BR0212089A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0212089-5A 2001-08-28 2002-08-27 Composições farmacêuticas para o tratamento de asma BR0212089A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Publications (1)

Publication Number Publication Date
BR0212089A true BR0212089A (pt) 2004-08-03

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212089-5A BR0212089A (pt) 2001-08-28 2002-08-27 Composições farmacêuticas para o tratamento de asma

Country Status (26)

Country Link
US (3) US20030114428A1 (https=)
EP (3) EP2092935B1 (https=)
JP (3) JP2005502675A (https=)
KR (1) KR100970531B1 (https=)
CN (2) CN1649568B (https=)
AR (1) AR036358A1 (https=)
AT (2) ATE503461T1 (https=)
AU (1) AU2002313828B2 (https=)
BR (1) BR0212089A (https=)
CA (1) CA2457926A1 (https=)
CO (1) CO5560551A2 (https=)
CY (2) CY1109212T1 (https=)
DE (2) DE60232251D1 (https=)
DK (2) DK2092935T3 (https=)
ES (3) ES2361805T3 (https=)
HU (1) HUP0401514A3 (https=)
MX (1) MXPA04001875A (https=)
NO (1) NO20041277L (https=)
NZ (1) NZ530987A (https=)
PE (1) PE20030390A1 (https=)
PL (1) PL209640B1 (https=)
PT (2) PT2092935E (https=)
SI (2) SI1420759T1 (https=)
TW (1) TWI324934B (https=)
WO (1) WO2003020253A2 (https=)
ZA (1) ZA200401419B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
WO2004018025A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
DK1542904T3 (da) * 2002-08-27 2008-04-21 Schering Corp Fremgangsmåde til fremstilling af formuleringer til en inhalator med målte doser
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
DE602005020113D1 (de) * 2004-01-21 2010-05-06 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
EP2444080A3 (en) * 2007-02-09 2012-05-02 Schering Corporation Stable Pharmaceutical Drug Aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP2244692A2 (en) * 2008-01-10 2010-11-03 Schering Corporation Inhalation drug products, systems and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2467136B1 (en) * 2009-12-07 2014-05-07 Raptor Therapeutics Inc. 4-methylpyrazole formulations
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
RU2629085C2 (ru) * 2011-10-11 2017-08-24 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Кристаллические микрочастицы бета-агониста, покрытые жирной кислотой
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
EA035261B1 (ru) 2014-05-07 2020-05-21 Бёрингер Ингельхайм Интернациональ Гмбх Небулайзер и контейнер
AU2015257878B2 (en) 2014-05-07 2019-08-08 Boehringer Ingelheim International Gmbh Container, nebulizer and use
CN106573082B (zh) 2014-06-30 2020-01-17 普罗沃锐斯科学有限公司 用于确定药物的递送剂量的量和均匀性的采样装置及相关方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3556348B1 (en) 2015-12-04 2021-02-03 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CA3016890A1 (en) 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN116583316A (zh) 2020-10-15 2023-08-11 普罗沃锐斯科学有限公司 用于吸入器测试的系统和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ZA924164B (en) * 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
EP0806940B1 (en) * 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
SK282147B6 (sk) * 1996-08-29 2001-11-06 Schering Corporation Aerosólový suspenzačný prípravok a jeho použitie
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
JP2003535042A (ja) * 2000-01-20 2003-11-25 バジリア ファルマスーチカ アーゲー 鼻腔に投与可能な環式ペプチド組成物
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
EP2092935A1 (en) 2009-08-26
JP2005502675A (ja) 2005-01-27
PL209640B1 (pl) 2011-09-30
TWI324934B (en) 2010-05-21
NZ530987A (en) 2006-08-31
HK1060972A1 (en) 2004-09-03
ES2361805T3 (es) 2011-06-22
US20050147565A1 (en) 2005-07-07
SI1420759T1 (sl) 2009-10-31
CA2457926A1 (en) 2003-03-13
KR100970531B1 (ko) 2010-07-16
JP5170789B2 (ja) 2013-03-27
ZA200401419B (en) 2005-01-26
CN101856362A (zh) 2010-10-13
EP1420759A2 (en) 2004-05-26
KR20040031002A (ko) 2004-04-09
JP2009185075A (ja) 2009-08-20
US20100143269A1 (en) 2010-06-10
EP1420759B1 (en) 2009-05-06
PL368897A1 (en) 2005-04-04
EP2092935B1 (en) 2011-03-30
CY1109212T1 (el) 2014-07-02
CY1111726T1 (el) 2015-10-07
HK1128428A1 (en) 2009-10-30
EP2319494A1 (en) 2011-05-11
HK1151987A1 (en) 2012-02-17
DE60232251D1 (de) 2009-06-18
WO2003020253A3 (en) 2003-05-22
DK2092935T3 (da) 2011-07-18
AR036358A1 (es) 2004-09-01
ES2325316T3 (es) 2009-09-01
WO2003020253A2 (en) 2003-03-13
DK1420759T3 (da) 2009-08-03
HUP0401514A3 (en) 2012-08-28
ES2389480T3 (es) 2012-10-26
PE20030390A1 (es) 2003-04-24
MXPA04001875A (es) 2004-06-15
CN1649568B (zh) 2010-10-27
NO20041277L (no) 2004-03-26
SI2092935T1 (sl) 2011-07-29
AU2002313828B2 (en) 2005-09-08
US20030114428A1 (en) 2003-06-19
HUP0401514A2 (hu) 2004-12-28
EP2319494B1 (en) 2012-06-13
DE60239648D1 (de) 2011-05-12
JP2010138184A (ja) 2010-06-24
PT2092935E (pt) 2011-05-31
CN1649568A (zh) 2005-08-03
ATE503461T1 (de) 2011-04-15
PT1420759E (pt) 2009-06-30
ATE430555T1 (de) 2009-05-15
CO5560551A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
BR0212089A (pt) Composições farmacêuticas para o tratamento de asma
GB0129260D0 (en) Pharmaceutical compositions and their uses
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
DE69933016D1 (de) Steroidale saponine zur behandlung der alzheimerischen krankheit
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
BR0214519A (pt) Inibidores de fator xa e outras serina proteases envolvidas na cascata da coagulação
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
HUP0201834A3 (en) Use of thyromimetic compounds for the manufacture of a pharmaceutical composition for the treatment of hair loss and such compositions
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
MY137435A (en) Retinoid compounds (i)
DE60311665D1 (de) Pharmazeutische zusammensetzungen
WO2001076601A3 (en) Pharmaceutical compositions comprising salmeterol and ipratropium
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
AU2002325687A1 (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
WO2002019995A3 (en) Pharmaceutical combination containing salmeterol and fluticasone
TH46568B (th) สารสกัดจากพืชเพื่อการบำบัดการกลับละลายกระดูก?ที่เพิ่มขึ้น
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 9/12, A61K 31/167, A61K 31/58, A61P 11/06

Ipc: A61K 9/12 (2011.01), A61K 31/167 (2011.01), A61K 3

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2321 DE 30-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.